Advanced search
1 file | 386.43 KB Add to list

Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance

Kathleen Lambein (UGent) , Mieke Van Bockstal (UGent) , Lies Vandemaele (UGent) , Sofie Geenen (UGent) , Isabelle Rottiers (UGent) , Ann Nuyts (UGent) , Bart Matthys (UGent) , Marleen Praet (UGent) , Hannelore Denys (UGent) and Louis Libbrecht (UGent)
Author
Organization
Abstract
Objectives: To investigate the clinical and pathobiological significance of distinguishing score 0 and score 1+ within the group of immunohistochemistry (IHC)-negative invasive breast cancers. Methods: We studied HER2 status using both IHC and fluorescence in situ hybridization (FISH) in 150 consecutive breast tumors submitted to our laboratory after a negative IHC result in local testing centers. Results: We were able to discern a group of score 0 tumors that had a lower HER2 copy number than the group consisting of score 1+ tumors. In contrast with the group of score 1+ tumors, HER2 FISH was consistently negative for both copy number based and ratio-based tumors without equivocal results. Conclusions: In a setting with stringent quality assurance, score 0 and score 1+ tumors emerge as distinct and clinically important subgroups within the HER2 IHC-negative population.
Keywords
Immunohistochemistry, HER2, FISH, Score 0, Score 1+, Breast cancer, IN-SITU HYBRIDIZATION, HERCEPTEST IMMUNOHISTOCHEMISTRY, SINGLE-INSTITUTION, AMERICAN-SOCIETY, RECEPTOR, ONCOLOGY/COLLEGE, RECOMMENDATIONS, SPECIFICITY, CONCORDANCE, EXPRESSION

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 386.43 KB

Citation

Please use this url to cite or link to this publication:

MLA
Lambein, Kathleen, Mieke Van Bockstal, Lies Vandemaele, et al. “Distinguishing Score 0 from Score 1+ in HER2 Immunohistochemistry-negative Breast Cancer: Clinical and Pathobiological Relevance.” AMERICAN JOURNAL OF CLINICAL PATHOLOGY 140.4 (2013): 561–566. Print.
APA
Lambein, Kathleen, Van Bockstal, M., Vandemaele, L., Geenen, S., Rottiers, I., Nuyts, A., Matthys, B., et al. (2013). Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 140(4), 561–566.
Chicago author-date
Lambein, Kathleen, Mieke Van Bockstal, Lies Vandemaele, Sofie Geenen, Isabelle Rottiers, Ann Nuyts, Bart Matthys, Marleen Praet, Hannelore Denys, and Louis Libbrecht. 2013. “Distinguishing Score 0 from Score 1+ in HER2 Immunohistochemistry-negative Breast Cancer: Clinical and Pathobiological Relevance.” American Journal of Clinical Pathology 140 (4): 561–566.
Chicago author-date (all authors)
Lambein, Kathleen, Mieke Van Bockstal, Lies Vandemaele, Sofie Geenen, Isabelle Rottiers, Ann Nuyts, Bart Matthys, Marleen Praet, Hannelore Denys, and Louis Libbrecht. 2013. “Distinguishing Score 0 from Score 1+ in HER2 Immunohistochemistry-negative Breast Cancer: Clinical and Pathobiological Relevance.” American Journal of Clinical Pathology 140 (4): 561–566.
Vancouver
1.
Lambein K, Van Bockstal M, Vandemaele L, Geenen S, Rottiers I, Nuyts A, et al. Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance. AMERICAN JOURNAL OF CLINICAL PATHOLOGY. 2013;140(4):561–6.
IEEE
[1]
K. Lambein et al., “Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance,” AMERICAN JOURNAL OF CLINICAL PATHOLOGY, vol. 140, no. 4, pp. 561–566, 2013.
@article{4412892,
  abstract     = {{Objectives: To investigate the clinical and pathobiological significance of distinguishing score 0 and score 1+ within the group of immunohistochemistry (IHC)-negative invasive breast cancers.
Methods: We studied HER2 status using both IHC and fluorescence in situ hybridization (FISH) in 150 consecutive breast tumors submitted to our laboratory after a negative IHC result in local testing centers.
Results: We were able to discern a group of score 0 tumors that had a lower HER2 copy number than the group consisting of score 1+ tumors. In contrast with the group of score 1+ tumors, HER2 FISH was consistently negative for both copy number based and ratio-based tumors without equivocal results.
Conclusions: In a setting with stringent quality assurance, score 0 and score 1+ tumors emerge as distinct and clinically important subgroups within the HER2 IHC-negative population.}},
  author       = {{Lambein, Kathleen and Van Bockstal, Mieke and Vandemaele, Lies and Geenen, Sofie and Rottiers, Isabelle and Nuyts, Ann and Matthys, Bart and Praet, Marleen and Denys, Hannelore and Libbrecht, Louis}},
  issn         = {{0002-9173}},
  journal      = {{AMERICAN JOURNAL OF CLINICAL PATHOLOGY}},
  keywords     = {{Immunohistochemistry,HER2,FISH,Score 0,Score 1+,Breast cancer,IN-SITU HYBRIDIZATION,HERCEPTEST IMMUNOHISTOCHEMISTRY,SINGLE-INSTITUTION,AMERICAN-SOCIETY,RECEPTOR,ONCOLOGY/COLLEGE,RECOMMENDATIONS,SPECIFICITY,CONCORDANCE,EXPRESSION}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{561--566}},
  title        = {{Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance}},
  url          = {{http://dx.doi.org/10.1309/AJCP4A7KTAYHZSOE}},
  volume       = {{140}},
  year         = {{2013}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: